Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy

Expert Rev Clin Pharmacol. 2021 Feb;14(2):141-143. doi: 10.1080/17512433.2021.1865797. Epub 2020 Dec 23.

Authors

Winnie W Y Sung¹, James C H Chow¹, William C S Cho¹

Affiliation

¹ Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

PMID: 33322961
DOI: 10.1080/17512433.2021.1865797

No abstract available

Keywords: Cancer immunotherapy; tissue-agnostic biomarker; tumor mutational burden.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor / metabolism*
Humans
Immunotherapy / methods*
Mutation
Neoplasms / genetics
Neoplasms / pathology
Neoplasms / therapy*

Substances

Biomarkers, Tumor